Antisense oligonucleotide targeting Livin induces apoptosis of human bladder cancer cell via a mechanism involving caspase 3 by Chuan, Liu et al.
Chuan et al. Journal of Experimental & Clinical Cancer Research 2010, 29:63
http://www.jeccr.com/content/29/1/63
Open Access RESEARCH
© 2010 Chuan et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Research Antisense oligonucleotide targeting Livin induces 
apoptosis of human bladder cancer cell via a 
mechanism involving caspase 3
Liu Chuan1, Wu Xiaohou*1, Luo Chunli3, Hu Zili2, Yin Zhikang1, He Yunfeng1, Du Hu1, Zhang Weili2, Jiang Qing2 and 
Lin Yanjun2
Abstract
Background and Aim: in recent years, Livin, a new member of IAPs family, is found to be a key molecule in cancers. 
Researchers consider Livin may become a new target for tumor therapy; however, the role of it in bladder cancer is still 
unclear. The purpose of this article is to investigate Antisense Oligonucleotide (ASODN) of Livin on treating bladder 
cancer cell and underlying mechanisms.
Methods: Phosphorathioate modifying was used to synthesize antisense oligonucleotides targeting Livin, followed by 
transfection into human bladder cancer cell 5637. After transfection, Livin mRNA and protein level, cell proliferation 
and apoptosis changes, caspase3 level and its effect on human bladder cancer transplantable tumor in nude mice 
were measured.
Result: results showed Livin ASODN effectively inhibited Livin expression and tumor cell proliferation, and these effects 
probably through enhanced caspase3 activity and apoptosis of tumor cells. In nude mice transplantable tumor model, 
Livin expressions were inhibited meanwhile caspase3 expression was increased. Tumor growth slowed down and 
apoptosis was enhanced.
Conclusion: Our data suggest that Livin plays an important role in inhibiting apoptosis of bladder cancer cells. Livin 
ASODN may promote cell apoptosis, inhibit bladder cancer growth, and become one of the methods of gene therapy 
for bladder cancer.
Introduction
Inhibition of apoptosis is one of the important mecha-
nisms for the growth of many malignant tumor cells.
IAPs, the new anti-apoptotic protein families which inde-
pendent of Bcl-2, are a hot apoptosis research field in
recent years, and can play an important role in inhibiting
tumor cell growth. Until now, 8 members of IAPs family
were found: NAIP[1], ILP-2[2], c-IAPl(MIHB, HIAP-2),
c-IAP2((HIAP-1, MIHC, API2)[3], XIAP(hILP, MIHA,
ILP-1)[4], Bruce(apollon)[5], survivin[6] and Livin(ML-
IAP, KIAP)[7]. Livin as a new member of IAPs family was
found in recent years, which shows high expression level
in some specific tumor tissue cells, but little, if not none,
in normal tissues. Researchers had found that it may
become the target for tumor therapy [8,9]. In 2003, Gaz-
zaniga et al [10] used RT-PCR in 30 cases of transitional
cell carcinoma of the bladder (TCCB) tumor tissue to
detect Livin mRNA expression level, and the results
showed that normal bladder tissues did not express Livin,
while TCCB tissues expressed high level of Livin. They
made a follow-up visit for 4 years to these patients and
finally discovered that the Livin positive expression was
quite related to the tumor recrudescence. So the objective
of this study is to apply antisense oligonucleotide for
Livin gene to investigate the effect of inhibition Livin
expression on proliferation and apoptosis of human blad-
der cancer cell 5637 in vivo and in vitro, and to further
explore the mechanisms under the phenomenon, and to
provide a theoretical basis for treatment of bladder can-
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cer using antisense oligonucleotide with Livin as a target
gene.
Materials and methods
Synthesis of antisense oligonucleotide
Livin antisense oligonucleotide sequence was from the
literature [11], and a misantisense oligonucleotides
(MSODN) was also designed. According to Genbank,
ASODN and MSODN do not match with any known
mammalian gene. They were synthesized by Takara Bio-
technology Co., Ltd (Dalian, China) with phosphorathio-
ate oligonucleotide technology followed by PAGE
purification. Using serum-free and antibiotic-free
RPMI1640 medium to dilute the stock solution to 20
μmo1/L followed by filtration of microporous filtering
film and preservation at -20°C. Antisense sequence: 5'-
ACCATCACCGGCTGCCCAGT-3', target sequence: 5'-
ACUGGGCAGCCGGUGAUGGU-3', missense
sequence: 5'-GTCAGGATCTTCCCACGGAG-3'.
Culture and transfection of human bladder cancer cell line 
5637
Human TCCB cell line 5637 was purchased from the
Institute of Cell Research, Shanghai, and Chinese Acad-
emy of Sciences. The cells were cultured in RPMI 1640
medium (Gibico, U.S.A.) supplemented with 10% fetal
bovine serum (FBS, Sijixin Inc., China) and 1% penicillin-
streptomycin (Invitrogen, U.S.A.). All cells were cultured
in 6-well plate at 37°C with 5% CO2. During the logarith-
mic growth phase, the liposome was respectively mixed
with antisense and missense oligonucleotides in serum-
free medium (Invitrogen, USA) in accordance with Lipo-
fectamine™ 2000 (Invitrogen, USA) instructions to form
liposome-oligonucleotide complexes, which were then
added into culture plate. The final concentration of oligo-
nucleotide was 160 nmolL-1. Seventy-two hours after
transfection, cells were harvested for RT-PCR, Western
Blot, cell immunofluorescence, flow cytometry analysis,
transmission electron microscope observation and
Caspase3 activity measurement.
3-(4, 5-Dimethylthiazol-2-yl)-2, 5-dimethyl tetrazolium 
bromide (MTT) assay for cell inhibition
Cells in logarithmic growth phase were seeded in 96-well
plates at 5 × 104 cells per well. Then cells were transfected
with antisense oligonucleotide of different concentrations
(the final concentrations are 0 nmol/L, 20 nmol/L, 40
nmol/L, 60 nmol/L, 80 nmol/L, 100 nmol/L, 120 nmol/L,
140 nmol/L, 160 nmol/L, 180 nmol/L, 200 nmol/L) for 6
hr, followed by culturing with nomal medium for 66 hr.
Four hours before stop culturing, 20 μL of 5 mg/mL MTT
(sigma, U.S.A.) was added to the culture medium. After
incubation, the culture medium was removed and 200 μL
of dimethylsulphoxide(DMSO) was added to resolve the
crystal. Absorbance was measured at 490 nm. Each sam-
ple was assayed for four times. Tumor cell inhibition rate
= (1 - treated group absorbance/control group absor-
bance) × 100%.
Semiquantitative RT-PCR
Total RNA was extracted from tissue homogenates or cell
lysates with TRIzol reagent (invitrogen, U.S.A.) and RT-
PCR was carried out with a RNA PCR Kit Ver.3.0
(TaKaRa, Japan) according to the kit's instructions. Livin-
specific primers discriminating between the α- and the β-
variant were: forward, 5'-GTCCCTGCCTCTGGGTAC-
3'; reverse, 5'-CAGGGAGCCCACTCTGCA-3'. Product
sizes 368 and 314 bp, respectively. The primers used for
GAPDH were: forward, Sense: 5'-ATGACATCAA-
GAAGGTGGTG-3'; reverse, 5'-CATACCAGGAAAT-
GAGCTTG-3', which yields a product of 177 bp. The
PCR condition was: 95°C for 2 min, then 38 cycles at 94°C
for 30 seconds, 64°C for 45 seconds, and 72°C for 30 sec-
onds in 1.5 mM MgCl2-containing reaction buffer. Five
μL of RT -PCR products were resolved on 1.5% agarose
gels. The gels were stained with ethidium bromide (EB)
and were scanned for densitometric estimation of the
Livin products with GAPDH products serving as the
internal control.
Western Blot Analysis
Proteins were extracted from cell lines as previous
described: Proteins were separated by 12% SDS poly-
acrylamide gel electrophoresis, transferred to an nitrocel-
lulose membrane (Millipore, USA), and detected with a
monoclonal anti-β-actin antibody (R&D systems, USA)
or polyclonal anti-Livin antibody (R&D systems, USA),
employing enhanced chemiluminescence (PIERCE,
USA).
Immunofluorescence, immunohistochemical and laser 
confocal microscope for expression of Livin
Cells were transfected with different reagents 72 hours
and then disposed the culture medium. Use 0.01 mol/L
PBS to rinse, and 4% paraformaldehyde to fix at room
temperature followed by reaction with 0.4% Triton-X100
at room temperature for 20 min. Add rabbit serum fol-
lowed by reaction for 30 min at room temperature. Add
primary antibody (goat anti-human Livin, R&D systems,
USA) and place it in a wet box for overnight at 4°C fol-
lowed by 0.01 mol/L PBS rinse. Add secondary antibody
labeled with FITC (rabbit anti-goat) and set it in a wet
box at room temperature for 1 h followed by 0.01 mol/L
PBS rinse and 50% glycerol mounting. Use laser scanning
confocal microscope (Leica Tcs Sp2) for observation and
imaging.
For immunohistochemical examination, tumor tissue
samples were fixed with 4% paraformaldehyde for 72 hr,
dehydrated in graded ethanol, and embedded in paraffinChuan et al. Journal of Experimental & Clinical Cancer Research 2010, 29:63
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followed by serial sections. SP kit, goat anti-human Livin
antibody, rabbit anti-human Caspase3 antibodies were
purchased from the American R&D systems. Immuno-
histochemistry staining: repair the antigen with trypsin,
add goat anti-human Livin antibodies or rabbit anti-
h u m a n  C a s p a s e 3  a n t i b o d y  f o l l o w e d  b y  P B S  w a s h i n g ,
DAB color development
Transmission electron microscope for cell morphology
After transfection, the cells in each group were centri-
fuged at 1500 rpm for 20 min, followed by fixing with 4%
paraformaldehyde for 1 hr, and then transferring into pre-
chilled 1% glutaraldehyde. The samples were dehydrated
in graded ethanol, embedded in epon 812, and then cut
into ultrathin or semithin sections. The sections were
stained and examined under a Hitachi H-600 transmis-
sion electron microscope.
Detection of apoptotic cells by flowcytometry
Cells were collected by low speed centrifugation and
washed with ice-cold PBS then recollected by centrifuga-
tion. After washing with PBS twice the cells were incu-
bated in 10 μl Annexin V-FITC (fluorescein
isothiocyanate) and 5 μl propidium iodine (PI) at 4°C for
30 minutes using the Annexin V-FITC apoptosis assay kit
(KeyGen Biotech. Co. Ltd. Nanjing, China). Finally, the
cells were analyzed within 60 minutes by flow cytometry.
Determination of Caspase3 activities by kinase assay
The experiments conformed to the operating instructions
provided by the kit (BioVision Inc.): cells were collected
and added with cell lysis solution followed by incubation
on ice for 10 min and centrifugation. The supernatant
was added with reaction buffer and coupling substrate
followed by 37°C water bath for 1 h. The absorbance val-
ues were determined by enzyme-linked assay at 405 nm
wavelength. The values were regarded as the relative
activity of Caspase3.
Nude mouse xenograft model
Female BALB/c nude mice, 4 weeks of age, weighting 16 ±
0.6 g, were purchased from Experimental Animal Center
of Chinese Academy of Sciences, Shanghai, China. Mice
were housed in microisolator cages in a specific patho-
gen-free (SPF) condition with 12-hr light-dark cycles.
Mice were subcutaneously implanted with 1 × 107 5637
cells. Once tumors reached approximately 60 μL in vol-
ume, the mice were allocated to receive either ASODN or
MSODN treatment, with the concentration of 200 nmol/
L and 0.2 ml/mice. The nude mice injected with ASODN
were termed as treatment group and the nude mice
i n j e c t e d  w i t h  M S O D N  w e r e  t e r m e d  a s  c o n t r o l  g r o u p .
Complexes of ASODN or MSODN plus 4 μL invivo-jet-
PEI™ (polyplus-transfection Inc., U.S.A.) and also plus
160 μL 5% glucose were directly injected into the tumor
once every other day with a total of 7 times. Tumor
dimensions were measured once every three days and the
tumor volumes calculated using the formula: 1/2 × a × b2,
where a and b respectively represented the larger and
smaller tumor diameter. At the end of the treatment,
mice were killed by overdose of ketamine (400 mg/kg)
and xylazine (50 mg/kg) and necropsy was performed.
Tumor tissue samples were prepared for Immunohis-
tochemistry or TUNEL cell apoptosis detection. Tumor
growth inhibition (TGI) was calculated using the formula
TGI (%) = (1-MT/MC) × 100, where MT and MC are the
mean tumor masses in the treatment group and control
group respectively.
TUNEL analyses for cell apoptosis detection
For detection of apoptosis, TUNEL analyses were per-
formed using the in situ cell death detection kit (Roche
Molecular Biochemicals, USA). Operations were carried
out according to kit instructions. 10 high-powerfields
were selected for each case. Count the number of apop-
totic cells and total number of cells for each powerfield to
calculate the percentage of apoptotic cells (number of
apoptotic cells in each powerfield/total cell number in
each powerfield) i.e., apoptosis index (AI).
.
Statistical analysis
The results were expressed as mean ± standard deviation.
One-way analysis of variance (ANOVA) was used to
determine the levels of difference between all groups.
Comparisons for all pairs were made using Student-New-
man-Keuls (SNK) test. p < 0.05 was considered statisti-
cally significant.
Results
Livin antisense oligonucleotide dose-dependently inhibit 
bladder cancer cell growth
After transfected with different concentrations of Livin
antisense oligonucleotides, cell growth of bladder cancer
cell lines was determined by MTT and an obvious dose-
dependently inhibitory effect was found (Fig 1). When
the Livin antisense oligonucleotide concentration was
160 nmol/L, the cell growth inhibition rate reached 92.61
percent, although reagent concentration was continu-
ously increasing, the inhibition rate will not increase sig-
nificantly (P > 0.05). Accordingly, we chose 160 nmol/L
oligonucleotide as the suitable concentration for further
study.
Livin mRNA and protein expression was inhibited after 
Livin ASODN transfection
To demonstrate the inhibitory effect of Livin ASODN on
Livin expression, RT-PCR, Western blot, and LSCM were
applied to detect the Livin mRNA and protein expressionChuan et al. Journal of Experimental & Clinical Cancer Research 2010, 29:63
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level in the cells of each group. In RT-PCR experiment,
Livin gene electrophoretic bands were seen at the posi-
tions of 314 bp and 368 bp relative to Marker in each
group, which demonstrated that 5637 cells expressed Liv-
inα and Livinβ. However, the brightness of the electro-
phoretic bands in antisense group was significantly lower
than the one in missense group, liposome group and PBS
group; while the brightness of the last three groups were
similar (Fig. 2a).
Then we performed Western blot to evaluate Livin pro-
tein expression. Confirmed with the results of RT-PCR,
the expression of Livinα and Livinβ in the antisense
group was significantly lower than the ones in missense
group, liposome group and PBS group, while the expres-
sion of Livinα and Livinβ in the last three groups were
similar (Fig. 2b).
Using laser scanning confocal microscopy (LSCM)
images, we found Livin-ir located in the cytoplasm and
nucleus with the majority in the nucleus. The intensity
and distribution of Livin-ir in PBS group, liposome group
and missense group cells were similar. After the transfec-
tion of Livin ASODN, the green fluorescence for marking
Livin significantly decreased with asymmetrical distribu-
tion. It was observed that the volume of some cells even
significantly reduced with no green fluorescence at all
(Fig. 3). Together, these data demonstrated that Livin
mRNA and protein expression were inhibited after Livin
ASODN transfection.
Cell morphology changed and apoptosis rate increased 
after transfection with Livin ASODN
As transfection Livin ASODN can inhibit bladder cancer
cell growth, we next wanted to confirm the mechanisms
underlying this inhibitory effect. Using transmission elec-
tron microscopy we found: Antisense group showed
more cell degeneration and necrosis, with cell volume
enlargement, chromatin margination and dissolving and
lipid droplets within the cytoplasm increase, endoplasmic
reticulum dilation, and swelling of mitochondria like vac-
uoles were observed. Occasional plasma membrane rup-
ture and cell collapse were seen. And a small amount of
apoptotic cells could also be seen: cell volume reduced,
matrix electron density increased, nuclear membrane
Figure 2 Livin mRNA and protein expression level in each group of cells. After transfected with Livin antisense oligonucleotides, (a) the Livin 
mRNA was decrease significantly (Lane 1: antisense group; 2: missense group; 3: Lipo group; 4: PBS group) and (b) the Livin protein was decrease sig-
nificantly(Lane 1: PBS group; 2: missense group; 3: Lipo group; 4: antisense group;), while the other three groups did not have significant difference.
Figure 1 Inhibitory rate of 5637 cells transfected with Livin 
ASODN. After the transfection of bladder cancer cell lines with differ-
ent concentrations of Livin antisense oligonucleotides, the inhibition 
effect on cell growth was determined by MTT and a clear dose-depen-
dence was found.Chuan et al. Journal of Experimental & Clinical Cancer Research 2010, 29:63
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invaginated, chromatin agglutinate until broken into
many small pieces. Cell plasma membrane inward shrunk
with the formation of apoptotic bodies in which nuclear
materials were visible. No significant changes in cell mor-
phology occurred in the other three control groups (Fig.
4).
To further confirm the increasing apoptosis rate, we
used flow cytometry to measure cell apoptosis. The
results showed cell apoptosis rate of antisense group with
Livin ASODN transfection (46.39 ± 9.23) % was signifi-
cantly higher than PBS group (4.54 ± 1.84) %, liposome
group (5.70 ± 1.61)%, and missense groups (5.10 ± 1.56)%
with P < 0.01. The apoptosis rates of the latter three
groups had no significant difference, P > 0.05. (Fig. 5).
Cellular caspase3 activities were increased after 
transfection with Livin ASODN
As Caspase3 is an important apoptosis inducing kinase,
we next detect the Caspase 3 activity in bladder cancer
cells after transfect with Livin ASODN. Results of
Caspase3 activity kinase method showed that after Livin
ASODN transfection into 5637 cells, the Caspase3 activ-
ity was significantly increased with the relative activity of
0.062 ± 0.018 (fig 6). Compared with missense group
(0.025 ± 0.011), liposome group (0.029 ± 0.016) and PBS
group (0.032 ± 0.016), the difference was significant with
P < 0.05. The latter three groups had no significant differ-
ence, P > 0.05. all this result indicated that Livin ASODN
may through increasing Caspase 3 activity to induce blad-
der cancer cell apoptosis and thus inhibit its growth.
Livin ASODN transfection inhibited 5637 tumor growth in 
vivo
As we had confirmed that Livin ASODN can effectively
inhibit bladder cancer cell growth by increasing its apop-
tosis, next we want to know whether this treatment effect
will appear in in vivo experiments. Nude mouse xeno-
graft model was describe as materials and methods previ-
ously, and tumor growth was observed continuously. In
addition, tumor size was measured and calculated at dif-
ferent times, and draw tumor growth curves. The results
showed that compared with the control group, the tumor
volume of antisense was significantly smaller than the
one of control group, P < 0.05 (Fig. 7) from the 18th day
after tumor inoculation until the 30th day, which indi-
cated that the injection of Livin ASODN inhibited tumor
growth. 30 days after inoculation of 5637 cells, the tumor
weight of MSODN injection group was 2.41 ± 0.41 g and
the tumor weight of ASODN inoculation group was1.31
Figure 4 The morphologic changes of each group cells observed 
by electromicroscope. Antisense group showed more cell degenera-
tion and necrosis, with cell volume enlargement, chromatin margin-
ation and dissolving and lipid droplets within the cytoplasm increase, 
endoplasmic reticulum dilation, and swelling of mitochondria like vac-
uoles. Occasional plasma membrane rupture and cell collapse were 
also seen. (a: control group(original magnification × 10000 b: antisense 
group(original magnification × 4000).
Figure 5 Cell apoptosis rate measurement. Antisense group 
showed increase of cell apoptosis rate (46.39 ± 9.23) %, while the other 
three groups did not have significant difference. *, p < 0.05.
Figure 3 Using confocal laser scanning microscope detects Livin 
Expression and location. After the transfection of Livin ASODN, the 
green fluorescence for marking Livin significantly decreased with un-
even distribution. It was observed that the volume of some cells signif-
icantly reduced with no green fluorescence at all, while the other three 
groups did not have significant difference. (a: PBS group; b: Lipo group; 
c: missense group; d: antisense group).Chuan et al. Journal of Experimental & Clinical Cancer Research 2010, 29:63
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± 0.88 g. t tests showed that the tumor weight of two
groups had significant difference with P < 0.05.
Cell apoptosis was induced after transfected with Livin 
ASODN in vivo
The microscope observation after TUNEL staining
showed that the center of positive cell nucleus was round
and uniform brown, which was the sign of DNA fragmen-
tation after TUNEL reaction in cells. The negative cells
had no cell morphological changes and were not colored
or only slightly stained. The results showed that: the
tumor cell morphologic of MSODN injection group was
normal. Only a small amount of cell nucleus was colored
and the cytoplasm was slightly stained. However, the
tumor cell nucleus of Livin ASODN injection group was
stained brown-red with nuclear enrichment. And the
cytoplasm was dispersedly and slightly stained (Fig. 8).
Randomly select 10 high power fields for each case to
calculate the apoptotic index (AI). The antisense group
apoptotic index was 19.60 ± 5.91, which was significantly
higher than the control group (3.48 ± 2.35), and the dif-
ference was significant with P < 0.05.
Livin expression was inhibited meanwhile Caspas 3 
expression was increased after transfection with Livin 
ASODN
Livin immunohistochemistry showed that the majority of
tumor cells in the tumor tissues of MSODN injection
group were stained dark brown, while the tumor cell
nucleus of ASODN injection group was stained pale yel-
low and the number of stained cells was small (Fig. 9a, b).
Figure 8 Apoptosis in tumor tissue of nude mice observed by 
TUNEL staining. The tumor cell nucleus of Livin ASODN injection 
group was stained brown-red with nuclear enrichment. And the cyto-
plasm was dispersedly and slightly stained. Randomly select 10 high 
power fields for each case to calculate the apoptotic index (AI). The an-
tisense group apoptotic index was 19.60 ± 5.91, which was significant-
ly higher than the control group (3.48 ± 2.35), and the difference was 
significant with P < 0.05(a Control group, b Livin ASODN group) (origi-
nal magnification ×400).
Figure 9 Livin and caspase 3 expression level in tumor tissue of 
nude mice. After injection of Livin ASODN, the Livin expression level in 
tumor tissue was significantly inhibited (a control group compare b 
ASOND group) and Caspase 3 expression was significantly increased (c 
control group compare with d ASOND group).
Figure 6 Caspase3 activities in the cells of each group. The results 
of kinase method to detect Caspase3 activity showed that after Livin 
ASODN transfection with 5637 cells, the Caspase3 activity was signifi-
cantly increased with the relative activity of 0.062 ± 0.018. Compared 
with missense group (0.025 ± 0.011), liposome group (0.029 ± 0.016) 
and PBS group (0.032 ± 0.016), the difference was significant with P < 
0.05. The latter three groups had no significant difference *, p < 0.05.
Figure 7 Comparison of tumor volume in nude mice injected with 
MSODN and ASODN. After injection of Livin ASODN, tumor volume 
was significantly smaller in ASODN group than in MSODN group from 
18 to 30 days. Tumor growth was inhibited by injection of ASODN 
compared with injection of MSODN. *, p < 0.05.Chuan et al. Journal of Experimental & Clinical Cancer Research 2010, 29:63
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Caspas 3 immunohistochemical staining showed that
the majority of tumor cells in the tumor tissues of
ASODN injection group were stained dark brown, while
the tumor cell caspas 3 staining of MSODN injection
group was relatively light, and the number of stained cells
was relatively small (Fig. 9c, d).
Discussion
In recent years, using EST clone containing the BIR
sequences, Vucic D, Kasof GM, etc. found Livin--a new
member of this gene family in human fetal kidney cDNA
library according to the IAPs homologous sequences
[12,13]. Livin produces two kinds of mRNA isomers in
the transcription process due to the different ways of
splicing. They have 1351 and 1297 base pairs, respec-
tively. In spite of the 54 bp difference in length, properties
of these two different mRNAs are exactly the same. The
proteins coded by them were 298 and 280 amino acids
with the molecular weight of about 33 kD and 30 kD, and
were respectively termed as Livin α and Livin β [14]. For
normal adults, most tissues do not express Livin at all
(except placenta), but in some cancer cell lines such as
melanoma cell lines (G361 and SK-Mel29), lymphoma,
HaCat cells, and MCF7 breast cancer cells [14], Livin is
highly expressed. In spite of that, Livin was also highly
expressed in a number of tumor tissues, such as bladder
cancer [10], lymphoma [13], lung cancer [15], hepatocel-
lular carcinoma[16], and renal carcinoma[17,18]. Gazza-
niga et al screened the apoptosis-related genes in bladder
transitional cell carcinoma tumor tissues, including Livin,
Survivin, BCL-X and BCL-2/BAX and so on, and then
performed a four-year follow-up visit. Results showed
that only Livin was related to bladder cancer recurrence
in these genes[10]. The tumor average recurrence time of
the patients with positive Livin expression after surgery
(3.5 months) was much less than the one of the patients
with negative Livin expression (27.2 months). The signifi-
cant differences of recurrence intervals indicated that
Livin expression is a sign of poor prognosis of early
superficial bladder cancer and it can be used as indicators
for monitoring recurrence of bladder cancer. As one of
the most common malignant tumors in urinary surgery,
the bladder cancer has the most remarkable characteris-
tics of easily postoperative recurrence. Therefore, Livin as
a target gene for treating bladder cancer has a good appli-
cation prospect.
Antisense nucleic acid is a naturally existing or syn-
thetic nucleotide sequence. Livin ASODN hybridizes
with target genes through Watson Crick principle of
complementary base pairing to prevent gene expression,
inhibit cell proliferation, promote apoptosis, and achieve
the purpose of preventing or treating tumors. The natural
oligonucleotide is easily degraded, but phosphorathioate
modifying can increase the capacity of its tolerance to
nucleic acid hydrolysis, with good solubility and hybrid-
ization properties. The effectiveness and safety have been
universally accepted by researchers. Currently the anti-
sense oligonucleotide with bcl-2 as the target gene (trade
name: Oblimersen) is in Phase III clinical trials with the
permit of FDA (mainly treat malignant melanoma,
chronic lymphocytic leukemia, multiple myeloma, etc.)
[19]. The drug achieves the purpose of cancer treatment
by inhibiting the expression of bcl-2 inside the tumor
cells and inducing the tumor cell apoptosis. There are
also a variety of antisense oligonucleotides anticancer
drugs in clinical trials [20,21]. In the present study, phos-
phorathioate modifying greatly enhanced the anti-
ribozyme decomposition capacity of Livin ASODN. The
supplement of cationic liposome transfection further
increased its stability and improved the ability of uptake
by cells. Using RT-PCR, Western blot, immunocy-
tochemistry, immunohistochemistry, we found that Livin
ASODN could inhibit the expression of Livin mRNA and
protein. We further observed that the cell growth was
inhibited and the apoptosis increased from MTT, flow
cytometry, TUNEL method and morphological observa-
tions.
Caspases protein plays an important role in apoptosis.
Most of the stimuli induce apoptosis through the Caspase
protein cascade activation reactions. Caspases protein
family has more than 10 members. Literatures have
reported that Livin can interact with Caspase-3, -6, -7, -8,
-9, -10 [22] (especially Caspase 3) to inhibit the process of
apoptosis. Using immunohistochemistry, we observed
that after the injection of Livin ASODN, the expression of
Caspase 3 in tumor tissues increased, which was probably
because Livin ASODN inhibited the expression of Livin
and then removed the binding inhibition to Caspase 3.
Besides, Caspase 3 removal function also enhanced,
which lead to increased cell apoptosis.
In conclusion, Livin ASODN could specifically inhibit
the expression of Livin in human bladder cancer cell 5637
and induce apoptosis of bladder cancer cells. It may be a
potential and most promising strategy for bladder cancer.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
LC is the first author of this paper and the most designing work was done by
him; WXH is the corresponding author. LCL carried out the cells experiments;
HZL carried out the transmission electron microscopy observation;YZK carried
out the immunohistochemical staining;HYF and DH participated in the study
design;ZWL carried out the data collection and statistic work; JQ and LYJ car-
ried out the animal works. All authors read and approved the final manuscript
Acknowledgements
This study was supported by research grant from Research Development 
Foundation of Health Bureau of ChongQing (No. 04-2-131).Chuan et al. Journal of Experimental & Clinical Cancer Research 2010, 29:63
http://www.jeccr.com/content/29/1/63
Page 8 of 8
Author Details
1Department of Urological Surgery, The First Affiliated Hospital, ChongQing 
Medical University, ChongQing 400016, PR China, 2Department of Urological 
Surgery, The Second Affiliated Hospital, ChongQing Medical University, 
ChongQing 400010, PR China and 3Faculty of Laboratory Medicine, 
ChongQing Medical University, ChongQing, 400016, PR China
References
1. Roy N, Mahadevan MS, McLean M: The gene for neuronal apoptosis 
inhibitory protein is partially deleted in individuals with spinal 
muscular atrophy.  Cell 1995, 80(1):167-178.
2. Richter BW, Mir SS, Eiben LJ: Molecular cloning of ILP-2, a novel member 
of the inhibitor of apoptosis protein family.  Mol Cell Biol 2001, 
21(13):4292-4301.
3. Rothe M, Pan MG, Henzel WJ: The TNFR2-TRAF signaling complex 
contains two novel proteins related to baculoviral inhibitor of 
apoptosis proteins.  Cell 1995, 83(7):1243-1252.
4. Liston P, Roy N, Tamai K: Suppression of apoptosis in mammalian cells 
by NAIP and a related family of IAP genes.  Nature 1996, 
379(6563):349-353.
5. Chen Z, Naito M, Hori S: A human IAP-family gene, apollon, expressed in 
human brain cancer cells.  Biochem Biophys Res Commun 1996, 
264(3):847-854.
6. Ambrosini G, Adida C, Altieri DC: A novel anti-apoptosis gene, survivin, 
expressed in cancer and lymphoma.  Nat Med 1997, 3(8):917-921.
7. Salvesen GS, Duckett CS: IAP proteins: blocking the road to death's 
door.  Nat Rev Mol Cell Biol 2002, 3(6):401-410.
8. Chang Hong, Shimmer Aaron D: Livin/melanoma inhibitor of apoptosis 
protein as a potential therapeutic target for the treatment of 
malignancy.  Mol Cancer Ther 2007, 6(1):24-30.
9. Liu B, Han M, Wen JK, Wang L: Livin/ML-IAP as a new target for cancer 
treatment.  Cancer Lett 2007, 250(2):168-176.
10. Gazzaniga P, Gradilone A, Giuliani L: Expression and prognostic 
significance of LIVIN, SURVIVIN and other apoptosis-related genes in 
the Progression of superficial bladder cancer.  Ann Oncol 2003, 
14(1):85-89.
11. Huadong Zhang, Shoujun Yuan, Huipeng Chen: Induction effects of 
antisense phosphorothioate oligodeoxynucleotide of livin mRNA on 
apoptosis in MCF-7 cells.  Chin J Clin Pharmacol Ther 2004, 
9(12):1353-1356.
12. Vucic D, Stennicke HR, Pisabarro MT: ML-IAP, a novel inhibitor of 
apoptosis that is preferentially expressed in human melanomas.  Curr 
Biol 2000, 10(21):1359-1366.
13. Kasof GM, Gomes BC: Livin, a novel inhibitor of apoptosis protein family 
member.  J Biol Chem 2001, 276(5):3238-3246.
14. Ashhab Y, Alian A, Polliack A: Two splicing variants of a new inhibitor of 
apoptosis gene with different biological properties and tissue 
distribution pattern.  FEBS Lett 2001, 495(1-2):56-60.
15. Hariu H, Hirohashi Y, Torigoe T: Aberrant expression and potency as a 
cancer immunotherapy target of inhibitor of apoptosis protein family, 
Livin/ML-IAP in lung cancer.  Clin Cancer Res 2005, 11(3):1000-1009.
16. Augello C, Caruso L, Maggioni M: Inhibitors of apoptosis proteins (IAPs) 
expression and their prognostic significance in hepatocellular 
carcinoma.  BMC Cancer 2009, 9(125):1471-2407.
17. Kempkensteffen C, Hinz S, Christoph F: Expression of the apoptosis 
inhibitor Livin in renal cell carcinomas: correlations with pathology and 
outcome.  Tumour Biol 2007, 28(3):132-138.
18. Crnković-Mertens I, Wagener N, Semzow J: Targeted inhibition of Livin 
resensitizes renal cancer cells towards apoptosis.  Cell Mol Life Sci 2007, 
64(9):1137-1144.
19. Adis International Limited: Oblimersen: Augmerosen, BCL-2 antisense 
oligonucleotide - Genta, G 3139 GC 3139, oblimersen sodium.  Drugs R 
D 2007, 8(5):321-334.
20. Geary RS, Bradley JD, Watanabe T: Lack of pharmacokinetic interaction 
for ISIS 113715, a 2'-0-methoxyethyl modified antisense 
oligonucleotide targeting protein tyrosine phosphatase 1B messenger 
RNA, with oral antidiabetic compounds metformin, glipizide or 
rosiglitazone.  Clin Pharmacokinet 2006, 45(8):789-801.
21. Chi KN, Eisenhauer E, Fazli L: A phase I pharmacokinetic and 
pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense 
oligonucleotide to clusterin, in patients with localized prostate cancer.  
J Natl Cancer Inst 2005, 97(17):1287-1296.
22. Vucic D, Franklin MC, Wallweber HJ: Engineering ML-IAP to produce an 
extraordinarily potent caspase 9 inhibitor: implications for Smac-
dependent anti-apoptotic activity of ML-IAP.  Biochem J 2005, 385(Pt 
1):11-20.
doi: 10.1186/1756-9966-29-63
Cite this article as: Chuan et al., Antisense oligonucleotide targeting Livin 
induces apoptosis of human bladder cancer cell via a mechanism involving 
caspase 3 Journal of Experimental & Clinical Cancer Research 2010, 29:63
Received: 21 April 2010 Accepted: 3 June 2010 
Published: 3 June 2010
This article is available from: http://www.jeccr.com/content/29/1/63 © 2010 Chuan et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Journal of Experimental & Clinical Cancer Research 2010, 29:63